No Data
No Data
Summary of the Semi-annual Report of Sichuan Baili Tianheng Pharmaceutical Co., Ltd. in 2024
Sichuan Baili Tianheng Pharmaceutical Co., Ltd. 2024 Interim Report
Express News | Sichuan Biokin Pharma Says It Returns to H1 Net Profit of 4.7 Bln Yuan
Sichuan Biokin Pharmaceutical Enrolls First Patient in Phase 3 Trial of Anti-Cancer Treatment; Shares Slide 3%
Baili Tianheng (688506.SH): The first subject has been enrolled in the Phase III clinical trial of BL-B01D1 (EGFR × HER3-ADC) for recurrent small cell lung cancer.
Bailitianheng (688506.SH) announced that the company's independently researched and developed innovative biological drug injection BL-B01D1...
Sichuan Biokin PharmaceuticalLtd (SHSE:688506) Has A Rock Solid Balance Sheet
No Data
No Data